- Home
- TEN vs SAGE Comparison
TEN vs SAGE Comparison
Compare TEN & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEN
- SAGE
- Stock Information
- Founded
- TEN 1993
- SAGE 2010
- Country
- TEN Greece
- SAGE United States
- Employees
- TEN N/A
- SAGE N/A
- Industry
- TEN
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- TEN
- SAGE Health Care
- Exchange
- TEN NYSE
- SAGE Nasdaq
- Market Cap
- TEN 480.8M
- SAGE 413.9M
- IPO Year
- TEN N/A
- SAGE 2014
- Fundamental
- Price
- TEN $18.18
- SAGE $6.46
- Analyst Decision
- TEN Buy
- SAGE Hold
- Analyst Count
- TEN 2
- SAGE 19
- Target Price
- TEN $31.00
- SAGE $9.88
- AVG Volume (30 Days)
- TEN 240.1K
- SAGE 815.0K
- Earning Date
- TEN 06-17-2025
- SAGE 04-29-2025
- Dividend Yield
- TEN 8.42%
- SAGE N/A
- EPS Growth
- TEN N/A
- SAGE N/A
- EPS
- TEN 5.03
- SAGE N/A
- Revenue
- TEN $804,061,000.00
- SAGE $47,404,000.00
- Revenue This Year
- TEN N/A
- SAGE $103.73
- Revenue Next Year
- TEN $11.19
- SAGE $41.15
- P/E Ratio
- TEN $3.61
- SAGE N/A
- Revenue Growth
- TEN N/A
- SAGE N/A
- 52 Week Low
- TEN $13.40
- SAGE $4.62
- 52 Week High
- TEN $31.48
- SAGE $13.47
- Technical
- Relative Strength Index (RSI)
- TEN 57.69
- SAGE 38.73
- Support Level
- TEN $17.59
- SAGE $6.36
- Resistance Level
- TEN $18.43
- SAGE $6.78
- Average True Range (ATR)
- TEN 0.52
- SAGE 0.24
- MACD
- TEN -0.05
- SAGE -0.01
- Stochastic Oscillator
- TEN 67.53
- SAGE 12.22
About TEN TSAKOS ENERGY NAVIGATION
Tsakos Energy Navigation Ltd is a seaborne transportation service provider for crude oil and petroleum products. The company's carriers cater to national and international independent oil companies and refiners. It generates revenue through charter contracts with its clients, which include time, bareboat, and voyage charters, contracts of affreightment, and pool arrangements.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.